{
    "nctId": "NCT04129216",
    "briefTitle": "The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer",
    "officialTitle": "The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "BASIC_SCIENCE",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "Change in Percent Expression of Ki67 Measured by Immunohistochemistry (IHC)",
    "eligibilityCriteria": "Inclusion criteria\n\n* Treatment-na\u00efve, histologically confirmed invasive ductal breast cancer between stages 1 to 3.\n* Co-enrollment in the FLEX Registry\n* Estrogen Receptor Positive (ER+) Progesterone Receptor Positive (PR+) confirmed hormone receptor status measured by immunohistochemistry (IHC)\n* Patients should understand patients' condition and be able to give informed consent to participate\n\nExclusion criteria\n\n* History of hormonal therapy, chemotherapy, radiation therapy, or novel therapy to treat the current breast cancer.\n* Allergic reactions/hypersensitivity to tamoxifen, letrozole, or exemestane or any of the ingredients of these drugs.\n* Any contraindication to hormonal therapy, such as history of thromboembolic disease or uterine cancer.\n* Patients without invasive disease (stage 0)\n* Patients with metastatic breast cancer(stageIV)\n* Patients that are Human Epidermal Growth Factor 2+(HER2+) by IHC/Fluorescence in situ hybridization (FISH).",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}